{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T07:38:24Z","timestamp":1771573104311,"version":"3.50.1"},"reference-count":10,"publisher":"Japanese Society of Internal Medicine","issue":"21","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2020,11,1]]},"DOI":"10.2169\/internalmedicine.3477-19","type":"journal-article","created":{"date-parts":[[2020,7,13]],"date-time":"2020-07-13T22:05:31Z","timestamp":1594677931000},"page":"2687-2691","source":"Crossref","is-referenced-by-count":4,"title":["Use of Rifampin Compared with Isoniazid for the Treatment of Latent Tuberculosis Infection in Japan: A Bayesian Inference with Markov Chain Monte Carlo Method"],"prefix":"10.2169","volume":"59","author":[{"given":"Kentaro","family":"Iwata","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Kobe University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naomi","family":"Morishita","sequence":"additional","affiliation":[{"name":"Department of Nursing, Hyogo Prefectural Kakogawa Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masami","family":"Nishiwaki","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Surgery, Hyogo Prefectural Kakogawa Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chisato","family":"Miyakoshi","sequence":"additional","affiliation":[{"name":"Department of Research Support, Center for Clinical Research and Innovation, Kobe City Medical Center General Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"publisher","unstructured":"1. Dye C, Scheele S, Dolin P, et al. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA 282: 677-686, 1999.","DOI":"10.1001\/jama.282.7.677"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Kawatsu L, Uchimura K, Ohkado A. Trend and treatment status of latent tuberculosis infection patients in Japan-Analysis of Japan TB Surveillance data. PLoS ONE 12: e0186588, 2017.","DOI":"10.1371\/journal.pone.0186588"},{"key":"3","unstructured":"3. Deciding When to Treat Latent TB Infection | Treatment | TB | CDC [Internet]. 2018 [cited 2019 Apr 5]. Available from: https:\/\/www.cdc.gov\/tb\/topic\/treatment\/decideltbi.htm"},{"key":"4","unstructured":"4. WHO. WHO | Latent TB Infection: Updated and consolidated guidelines for programmatic management [Internet]. [cited 2019 Apr 5]. Available from: http:\/\/www.who.int\/tb\/publications\/2018\/latent-tuberculosis-infection\/en\/"},{"key":"5","unstructured":"5. Treatment Regimens for Latent TB Infection | Treatment | TB | CDC [Internet]. 2019 [cited 2019 Apr 5]. Available from: https:\/\/www.cdc.gov\/tb\/topic\/treatment\/ltbi.htm"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Menzies D, Adjobimey M, Ruslami R, et al. Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults. N Engl J Med 379: 440-453, 2018.","DOI":"10.1056\/NEJMoa1714283"},{"key":"7","unstructured":"7. The Prevention Committee and the Treatment Committee of the Japanese Society for Tuberculosis. Treatment guideline for treatment of latent tuberculosis infection. Kekkak 89: 21-37, 2014."},{"key":"8","unstructured":"8. Gupta SK. Use of Bayesian statistics in drug development: advantages and challenges. Int J Appl Basic Med Res 2: 3-6, 2012."},{"key":"9","unstructured":"9. van de Schoot R, Kaplan D, Denissen J, Asendorpf JB, Neyer FJ, van Aken MA. A gentle introduction to Bayesian analysis: applications to developmental research. Child Dev 85: 842-860, 2014."},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Tuberculosis Research Committee (RYOKEN), Tokyo, Japan. Nationwide survey of anti-tuberculosis drug resistance in Japan. Int J Tuberc Lung Dis 19: 157-162, 2015.","DOI":"10.5588\/ijtld.13.0905"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/59\/21\/59_3477-19\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,7]],"date-time":"2020-11-07T03:48:00Z","timestamp":1604720880000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/59\/21\/59_3477-19\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,1]]},"references-count":10,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.3477-19","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,1]]}}}